Return on Assets (ROA): Rigel Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds ...
Rigel & Rigel, one of Rome’s longest-standing chiropractic practices, is proudly celebrating 55 years of continuous service, ...
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied ...
Four months ago, Rigel Pharmaceuticals spent just $2 million—plus ponying up another $233 million in potential milestones—to acquire Forma Therapeutics’ leukemia drug Rezlidhia. On Thursday, Rigel got ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026. Rigel senior ...
Zacks Investment Research on MSN
Will Tavalisse continue to drive Rigel Pharmaceuticals' growth in 2026?
Rigel Pharmaceuticals RIGL had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year ...
CEO Raul Rodriguez highlighted "year-over-year net product sales growth of 68%" and total revenue of $53.3 million for Q1 2025. He noted that Rigel achieved $11.4 million in net income for the quarter ...
Zacks Investment Research on MSN
Rigel Pharmaceuticals (RIGL) earnings expected to grow: Should you buy?
Rigel Pharmaceuticals (RIGL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports ...
Rigel’s IRAK1/4 inhibitor, R289, has shown promising results in a Phase 1b trial for relapsed/refractory lower-risk myelodysplastic syndrome (LR-MDS). The initial data presented at ASH 2024 ...
Shares of Rigel Pharmaceuticals (RIGL 2.83%) recently popped after the company announced a collaboration deal with one of America's largest drugmakers, Eli Lilly (LLY +2.76%). Despite more than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results